

Trethera Appoints Dr. Johanna Holldack as President and CEO

Beverly Hills, CA, 1st November 2015 – Trethera, a biotechnology company focused on the discovery and development of innovative small molecules for the treatment of hematological and solid tumors today announced the appointment of Dr. Johanna Holldack as President and Chief Executive Officer. The appointment is effective immediately.

Dr. Holldack brings 25 years of biotechnology and pharmaceutical industry experience. She has held various managerial positions in companies ranging from start-ups to big pharma, notably as CEO of Borean Pharma and then Telormedix. Before this, she was COO of MediGene AG and VP of Chiron Corporation. Dr. Holldack also had a role as Venture Partner at Swiss-based Aravis. Further background information is included below.

Trethera is discovering and developing innovative small molecules that precisely control nucleotide metabolism and DNA replication and integrity for the treatment of malignant diseases. The Company is building a pipeline of oncology products by harnessing its proprietary technology platform which is based on a deep understanding of the regulatory checkpoints in the complex system of nucleotide metabolism.

Trethera's lead compound DI-87 (TRE-515) is advancing through pre-clinical development with programs in both Leukemia and Solid Tumors. It is an oral small molecule inhibitor of Deoxycytidine Kinase, a key enzyme implicated in cancer cell proliferation. TRE-515 is anticipated to enter clinical trials in late 2017.

“Johanna is a highly seasoned executive and offers all the necessary experience and leadership qualities required to take Trethera to its next stage of development.” **said Johannes Czernin, Founder and Chairman of the Board of Trethera.** *“Her experience in drug development will be invaluable as we move our drug candidates into the clinic and continue to grow the Company.”*

Dr. Holldack, the newly appointed CEO, added: *“Trethera is entering a key phase of its corporate development with our first lead candidate about to enter the clinic. I look forward to working with such an outstanding group of people, further shaping Trethera's strategy as it advances the development of innovative therapeutics in order to make a difference in the treatment of cancer.”*

Background on Dr. Johanna Holldack, MD

Dr. Holldack has worked in the pharmaceutical industry for more than 20 years, where she has held key positions in both start-up and large pharma companies. Her experience includes management and executive positions at Behringwerke, Chiron, MediGene and Borean Pharma.

Dr. Holldack has a medical degree from Georg-August-University in Gottingen, Germany and is a Board Certified pediatrician. In addition, she has held positions as an assistant professor at the University of Essen, research fellow for the Deutsche Krebshilfe and a research associate at Harvard Medical School.

-End-



For more information, please contact:

Trethera
Dr. Johanna Holldack, CEO

Tel: +1 310 997 278
jholldack@trethera.com

Instinctif Partners
Dr. Christelle Kerouedan

Tel: +44 (0)20 7457 2020
trethera@instinctif.com

NOTES TO EDITORS

About Trethera

Trethera is a biotechnology company focused on the discovery and development of innovative small molecules that precisely control nucleotide metabolism and DNA replication and integrity for the treatment of malignant diseases.

The Company is building a pipeline of oncology products by harnessing its proprietary technology platform which is based on regulatory checkpoints in the complex system of nucleotide metabolism.

Trethera's lead compound DI-87 (TRE-515) is advancing through pre-clinical development with programs in both Leukemia and Solid Tumors. It is an oral small molecule inhibitor of Deoxycytidine Kinase, an important enzyme implicated in cancer cell proliferation. TRE-515 is being developed as a combination therapy and it is anticipated that the first clinical trial will commence in the second half of 2017.

The Company has a strong and growing patent position and an exclusive license from UCLA for patents relating to its platform and Deoxycytidine Kinase Inhibitors. The research behind the technology and products has received competitive grants and departmental funds totaling millions of dollars over the past eight years.

Trethera is located in California, U.S.

For more information, please visit the website: www.trethera.com.